12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PRO 140: Phase IIb start

Next half, CytoDyn said Drexel University College of Medicine will begin the placebo-controlled, U.S. Phase IIb NIDA and NIAID trials of PRO 140 to treat HIV infection. NIDA will evaluate PRO 140 in combination with highly...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >